Cargando…
Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given th...
Autores principales: | Cholongitas, Evangelos, Pipili, Chrysoula, Papatheodoridis, George V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295158/ https://www.ncbi.nlm.nih.gov/pubmed/28217256 http://dx.doi.org/10.4254/wjh.v9.i4.180 |
Ejemplares similares
-
Sofosbuvir: a novel oral agent for chronic hepatitis C
por: Cholongitas, Evangelos, et al.
Publicado: (2014) -
Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study
por: Darema, Maria, et al.
Publicado: (2020) -
Hepatitis B in renal transplant patients
por: Marinaki, Smaragdi, et al.
Publicado: (2017) -
Emerging role of cell-free DNA in kidney transplantation
por: Chopra, Bhavna, et al.
Publicado: (2021) -
Tregs and kidney: From diabetic nephropathy to renal transplantation
por: Dousdampanis, Periklis, et al.
Publicado: (2016)